Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a better blood pressure reading save kidneys?

NCT ID NCT05163158

Disease control Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether using central blood pressure (measured near the heart) instead of the usual arm cuff leads to better outcomes in 116 people with advanced chronic kidney disease. Participants were randomly assigned to either a central BP target or a standard arm BP target, both aiming for under 130 mmHg. The goal was to see if this approach is feasible and reduces artery stiffness after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Central blood pressure measurement
What this could lead to
If successful, this could show that using central blood pressure readings leads to better blood pressure management and fewer heart and kidney complications in advanced kidney disease patients.
What could go wrong
This is a small pilot study focused on feasibility, not on proving clinical benefits. The results may not confirm that central BP targeting is better than standard care, and larger trials are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

116 people

The number who actually took part.

Started

May 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Over 18 years of age; 2. eGFR \<30 mL/min/1.73m2 as determined by the CKD-EPI equation (within 30 days of screening); 3. Office brachial cuff systolic blood pressure between 120 and 160 mmHg (using automated office blood pressure). Exclusion Criteria: 1. Already taking 5 or more anti-hypertensive medications (any class) 2. Unwillingness to change anti-hypertensive medication by the attending Nephrologist or patient 3. Recent acute kidney injury (\>50% increase in serum creatinine in preceding 30 days) 4. Previous kidney replacement therapy (kidney transplant, hemodialysis or peritoneal dialysis) 5. Recent myocardial infarction, stroke, heart failure (in preceding 30 days) 6. Recent injurious fall requiring hospitalisation (in preceding 30 days) 7. Concomitant major illness / comorbidity that may result in death in the next 6 months 8. Participation in another study that is likely to affect BP levels 9. Inability to provide consent due to cognitive impairment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease stage 5 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Hypertension

Contacts and locations

Locations

  • Hôpital du Sacré-Coeur de Montréal

    Montreal, Quebec, H4J1C5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.